+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neurocognitive, academic and functional outcomes in survivors of infant ependymoma (UKCCSG CNS 9204)

Neurocognitive, academic and functional outcomes in survivors of infant ependymoma (UKCCSG CNS 9204)

Child's Nervous System 35(3): 411-420

This is the first UK multi-centre case-controlled study with follow-up in excess of 10 years to report the neurocognitive, academic and psychological outcomes of individuals diagnosed with a brain tumour in early childhood. Children enrolled into the UKCCSG CNS 9204 trial, diagnosed with intracranial ependymoma when aged ≤ 36 months old, who received a primary chemotherapy strategy to defer or avoid radiotherapy, were recruited. Outcomes of those who relapsed and subsequently received radiotherapy (n = 13) were compared to those enrolled who did not relapse (n = 16), age-matched controls-diagnosed with solid non-central nervous system (SN-CNS; n = 15) tumours or low-grade posterior fossa pilocytic astrocytoma (PFPA; n = 15), and normative data. Analyses compared nine neurocognitive outcomes as primary measures with quality of survival as secondary measures. Relapsed ependymoma participants performed significantly worse than their non-relapsed counterparts on measures of Full Scale IQ, Perceptual Reasoning, Word Reading and Numerical Operations. The relapsed ependymoma group performed significantly worse than SN-CNS controls on all primary measures, whereas non-relapsing participants only differed significantly from SN-CNS controls on measures of Processing Speed and General Memory. Relapsed ependymoma participants fared worse than all groups on measures of quality of survival. The relapsed irradiated ependymoma group demonstrated the most significantly impaired neurocognitive outcomes at long-term follow-up. Non-relapsing participants demonstrated better outcomes than those who relapsed. Results tentatively suggest avoiding radiotherapy helped preserve neurocognitive and learning outcomes of individuals diagnosed with ependymoma when aged ≤ 36 months old. Prospective neurocognitive surveillance is required. Recommendations for clinical and research practice are provided.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066010926

Download citation: RISBibTeXText

PMID: 30554263

DOI: 10.1007/s00381-018-4015-3

Related references

Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. European Journal of Cancer 46(1): 120-133, 2010

Neurocognitive Predictors of Academic Outcomes Among Childhood Leukemia Survivors. Cancer Nursing 39(4): 255-262, 2017

Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes. Neuro-Oncology 13(5): 536-545, 2011

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors. Acta Neuropathologica 128(1): 151-153, 2014

Neurocognitive outcomes in survivors of childhood cancer. Journal of Pediatric Psychology 30(1): 51-63, 2004

Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet. Oncology 8(8): 696-705, 2007

Neurocognitive outcomes in survivors of pediatric E-CPR: Has the Golden age arrived?. Resuscitation 139: 353-355, 2019

Neurocognitive and Psychosocial Outcomes in Pediatric Brain Tumor Survivors. Bioengineering 5(3):, 2018

Neurocognitive and behavioral outcomes in Latino childhood cancer survivors. Pediatric Blood and Cancer 60(10): 1696-1702, 2013

Neurocognitive and Academic Outcomes at Age 10 Years of Extremely Preterm Newborns. Pediatrics 137(4): -, 2016

Neurocognitive Outcomes and Interventions in Long-Term Survivors of Childhood Cancer. Journal of Clinical Oncology 36(21): 2181-2189, 2018

Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. JAMA Oncology 2(2): 201-208, 2016

Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 31(17): 2182-2188, 2013

Neurocognitive outcomes in congenital diaphragmatic hernia survivors: a cross-sectional prospective study. Journal of Pediatric Surgery 51(10): 1627-1634, 2016

Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma. Cancer 124(2): 417-425, 2018